BlackRock, Inc. Increases Stake in Corvus Pharmaceuticals Inc to 6.4%

On April 27, 2026, BlackRock, Inc. filed a Schedule 13G/A with the SEC, reporting a significant increase in its stake in Corvus Pharmaceuticals Inc (CRVS). As of the event date on March 31, 2026, BlackRock beneficially owns 5,387,818 shares of common stock, representing a 6.4% ownership interest in the company. This filing marks an amendment to a previous position, which was recorded as zero, indicating a new substantial holding for the investment firm. According to the filing, BlackRock holds sole dispositive power over all 5,387,818 shares and sole voting power over 5,320,965 shares. The securities were acquired in the ordinary course of business and are not held for the purpose of influencing or changing the control of the issuer. Various subsidiaries of BlackRock are identified as the owners of the shares, though no single person's interest exceeds five percent of the total outstanding common shares. This move positions BlackRock as a major institutional investor in the South San Francisco-based pharmaceutical company.